Immunoglobulin D amyloidosis: A distinct entity

Blood

Volumn 119, Issue 1, 2012, Pages 44-48

  Gertz, Morie A ^a   Buadi, Francis K ^a   Hayman, Suzanne R ^a   Dingli, David ^a   Dispenzieri, Angela ^a   Greipp, Philip R ^a   Kumar, Shaji K ^a   Lacy, Martha Q ^a   Lust, John A ^a   Leung, Nelson ^a   Rajkumar, S Vincent ^a   Russell, Stephen J ^a   Zeldenrust, Steven R ^a   Mikhael, Joseph R ^b   Roy, Vivek ^c   Kyle, Robert A ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARMUSTINE; COLCHICINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN D; IMMUNOGLOBULIN D ANTIBODY; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HEART DISEASE; HUMAN; KIDNEY DISEASE; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; OVERALL SURVIVAL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84862962978     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-358895     Document Type: Article

References (29)

1. Jancelewicz Z, Takatsuki K, Sugai S, PruzanskiW. IgD multiple myeloma: review of 133 cases. Arch Intern Med. 1975;135(1):87-93.
2. White GC 2nd, Jacobson RJ, Binder RA, Linke RP, Glenner GG. Immunoglobulin D myeloma and amyloidosis: immunochemical and structural studies of Bence Jones and amyloid fibrillar proteins. Blood. 1975;46(5):713-722.
3. Wechalekar A, Amato D, Chen C, Keith Stewart A, Reece D. IgD multiple myeloma: a clinical profile and outcome with chemotherapy and autologous stem cell transplantation. Ann Hematol. 2005;84(2):115-117. (Pubitemid 40089768)
4. Bladé J, Kyle RA. IgD monoclonal gammopathy with long-term follow-up. Br J Haematol. 1994;88(2):395-396. (Pubitemid 24318192)
5. Kim MK, Suh C, Lee DH, et al. Korean Multiple Myeloma Working Party. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Ann Oncol. 2011;22(2):411-416.
6. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564-569. (Pubitemid 34438817)
7. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21-33. (Pubitemid 36033957)
8. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32(1):45-59. (Pubitemid 24370135)
9. Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol. 1999;17(1):262-267. (Pubitemid 29022401)
10. Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA. Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. Med Oncol. 1999;16(2):104-109. (Pubitemid 29349856)
11. Shohat-Zabarski R, Kusniec J, Strasberg B. Perforation of the right ventricular free wall by an active fixation transvenous cardioverter defibrillator lead. Pacing Clin Electrophysiol. 1999;22(7):1118-1119. (Pubitemid 29361916)
12. Friman C, Tornroth T, Wegelius O. IgD myeloma associated with multiple extramedullary amyloidcontaining tumors and amyloid casts in the renal tubules. Ann Clin Res. 1970;2(2):161-166.
13. Nashel DJ, Widerlite LW, Pekin TJ Jr. IgD myeloma with amyloid arthropathy. Am J Med. 1973;55(3):426-430.
14. Isobe T, Osserman EF. Patterns of amyloidosis and their association with plasma-cell dyscrasia, monoclonal immunoglobulins and Bence-Jones proteins. N Engl J Med. 1974;290(9):473-477.
15. Kubo Y, Morita T, Koda Y, Hirasawa Y. Two types of glomerular lesion in non-amyloid immunoglobulin deposition disease: a case report of IgD-lambda myeloma. Clin Nephrol. 1990;33(6):259-263. (Pubitemid 20205929)
16. Tichý M, Mateja F, Urban P, Matuska M. IgD paraproteinemias. Neoplasma. 1993;40(1):59-61. (Pubitemid 23138975)
17. Sakurai-Chin C, Ubara Y, Suwabe T, et al. AL amyloidosis with IgD-lambda monoclonal gammopathy and lambda-type Bence-Jones protein: successful treatment by autologous stem cell transplantation. Clin Exp Nephrol. 2010;14(5):506-510.
18. Bladé J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994;12(11):2398-2404. (Pubitemid 24346713)
19. Hoag G, MacPherson M, Cuthbert D. Clinical pathology rounds: immunoglobulin D myeloma. Lab Med. 1995;26(10):639-642.
20. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. The Nordic Myeloma Study Group. Renal function in newly diagnosed multiple myeloma: a demographic study of 1353 patients. Eur J Haematol. 1994;53(4):207-212. (Pubitemid 24347964)
21. Morris C, Drake M, Apperley J, et al. Myeloma Subcommittee of Chronic Leukaemia Working Party of EBMT. Efficacy and outcome of autologous transplantation in rare myelomas. Haematologica. 2010;95(12):2126-2133.
22. Siragusa S, Morice W, Gertz MA, et al. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma: a series of 144 cases and a review of the literature. Ann Hematol. 2011;90(1):101-106.
23. Kumar SK, Gertz MA, Lacy MQ, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011;86(1):12-18.
24. Jimenez-Zepeda VH, Franke N, Delgado D, et al. High-dose melphalan for AL amyloidosis: the importance of case selection to improve clinical outcomes [abstract]. Blood. 2010;116:2403.
25. Gertz MA, Lacy MQ, Dispenzieri A, et al. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma. 2010;51(12):2181-2187.
26. Sanchorawala V, Finn KT, Fennessey S, et al. Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood. 2010;116(11):1990-1991.
27. Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood. 2010;116(23):4777-4782.
28. Kumar S, Hayman SR, Buadi F, et al. A phase II trial of lenalidomide, cyclophosphamide and dexamethasone (RCD) in patients with light chain amyloidosis [abstract]. Blood. 2009;114(22):1482.
29. Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011;118(4):865-873.